First-in-human biomarker-driven phase I trial of the potent and selective glutaminase-1 (GLS1) inhibitor IACS-6274 (IPN60090) in patients (pts) with molecularly selected advanced solid tumors.
Year: 2021
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Timothy A. Yap, Ecaterina Elena Dumbrava, Jordi Rodon Ahnert, David S. Hong, Shubham Pant, Daniel D. Karp, Sarina Anne Anne Piha-Paul, Vivek Subbiah, Apostolia Maria Tsimberidou, Siqing Fu, Filip Janku, Sandra Montez, Majd T Ahmad-Taha, Darlene Guerrero, Natalya N. Nazarenko, Yan Moore, Michael Soth, Jeff Kovacs, Timothy P. Heffernan, Philip Jones
Institution: The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W3170159148